JP7050792B2 - ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 - Google Patents

ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 Download PDF

Info

Publication number
JP7050792B2
JP7050792B2 JP2019540420A JP2019540420A JP7050792B2 JP 7050792 B2 JP7050792 B2 JP 7050792B2 JP 2019540420 A JP2019540420 A JP 2019540420A JP 2019540420 A JP2019540420 A JP 2019540420A JP 7050792 B2 JP7050792 B2 JP 7050792B2
Authority
JP
Japan
Prior art keywords
group
alkyl
pyrazine
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019540420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514315A5 (enExample
JP2020514315A (ja
Inventor
マティアス エックハルト
ホルガー ワグナー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020514315A publication Critical patent/JP2020514315A/ja
Publication of JP2020514315A5 publication Critical patent/JP2020514315A5/ja
Application granted granted Critical
Publication of JP7050792B2 publication Critical patent/JP7050792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019540420A 2017-01-26 2018-01-22 ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 Active JP7050792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17153390.4 2017-01-26
EP17153390 2017-01-26
PCT/EP2018/051390 WO2018138030A1 (en) 2017-01-26 2018-01-22 Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2020514315A JP2020514315A (ja) 2020-05-21
JP2020514315A5 JP2020514315A5 (enExample) 2021-01-14
JP7050792B2 true JP7050792B2 (ja) 2022-04-08

Family

ID=57906579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019540420A Active JP7050792B2 (ja) 2017-01-26 2018-01-22 ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用

Country Status (5)

Country Link
US (1) US10603317B2 (enExample)
EP (1) EP3573969A1 (enExample)
JP (1) JP7050792B2 (enExample)
CN (1) CN110312714B (enExample)
WO (1) WO2018138030A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248929B (zh) * 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10913720B2 (en) * 2017-01-26 2021-02-09 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138026A1 (en) * 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
WO2008066097A1 (fr) 2006-12-01 2008-06-05 Astellas Pharma Inc. Dérivé d'acide carboxylique
JP2012505896A (ja) 2008-10-15 2012-03-08 アムジエン・インコーポレーテツド スピロ環ｇｐｒ４０調節因子
JP2012508260A (ja) 2008-11-10 2012-04-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼの阻害剤として有用な化合物
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
JP2020505393A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP2020505400A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP2020505402A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP2020505394A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US628476A (en) 1898-03-18 1899-07-11 Joseph Howard Kirk Junction of cycle, motor-car, or other frames, &c.
US2505322A (en) 1945-09-14 1950-04-25 Gibson Refrigerator Co Refrigerator cabinet
US2560111A (en) 1946-11-07 1951-07-10 Raymond T Levine Buffing chuck
US2656003A (en) 1948-02-27 1953-10-20 Inst Of Inventive Res High explosive disk-shaped charge for seismic exploration
US2727340A (en) 1953-08-31 1955-12-20 Alfred S Zanotta Portable tool for reconditioning crane rails
US5356287A (en) 1987-03-16 1994-10-18 Mcintyre Kevin M Simulating presence
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CA2560111A1 (en) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
ATE517867T1 (de) 2005-02-15 2011-08-15 Glaxo Group Ltd Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
WO2006103503A1 (en) 2005-03-28 2006-10-05 Pfizer Japan Inc. Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US7664629B2 (en) 2005-07-19 2010-02-16 Xerox Corporation Second language writing advisor
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US20090036473A1 (en) 2006-03-15 2009-02-05 William Dalby Brown Novel quinazolinone derivatives and their medical use
MX2008012529A (es) 2006-03-30 2008-10-14 Asahi Kasei Pharma Corp Derivado biciclico substituido y uso del mismo.
JP4401428B2 (ja) 2006-06-27 2010-01-20 武田薬品工業株式会社 縮合環化合物
EP2289868B1 (en) 2008-06-25 2014-08-13 Daiichi Sankyo Company, Limited Carboxylic acid compound
ES2345916B1 (es) 2008-10-14 2011-09-14 Clipdorfix, S.L. Dispositivo de fijacion liberable de elementos adosados.
WO2010051819A1 (en) 2008-11-10 2010-05-14 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
US20120302566A1 (en) 2010-12-01 2012-11-29 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015009376A2 (pt) 2012-11-28 2017-07-04 Boehringer Ingelheim Int ácidos indaniloxidihidrobenzofuranilacéticos
WO2014086712A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
CA2900348C (en) 2013-02-28 2021-06-22 Sk Chemicals Co., Ltd. Tricyclic compound and use thereof
WO2015024526A1 (en) 2013-08-23 2015-02-26 Fujian Haixi Pharmaceuticals Co., Ltd Carboxylic acid compounds in treatment of diabetes mellitus
CN110300755B (zh) 2017-02-08 2022-10-04 勃林格殷格翰国际有限公司 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
WO2008066097A1 (fr) 2006-12-01 2008-06-05 Astellas Pharma Inc. Dérivé d'acide carboxylique
JP2012505896A (ja) 2008-10-15 2012-03-08 アムジエン・インコーポレーテツド スピロ環ｇｐｒ４０調節因子
JP2012508260A (ja) 2008-11-10 2012-04-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼの阻害剤として有用な化合物
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
JP2020505393A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP2020505400A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP2020505402A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP2020505394A (ja) 2017-01-26 2020-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Takano, Rieko et al.，Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists，Bioorganic & Medicinal Chemistry Letters，2014年，vol.24, no.13，pp.2949-2953

Also Published As

Publication number Publication date
US20190381037A1 (en) 2019-12-19
JP2020514315A (ja) 2020-05-21
US10603317B2 (en) 2020-03-31
EP3573969A1 (en) 2019-12-04
CN110312714A (zh) 2019-10-08
WO2018138030A1 (en) 2018-08-02
CN110312714B (zh) 2022-12-09

Similar Documents

Publication Publication Date Title
JP7050792B2 (ja) ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7049349B2 (ja) ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7050791B2 (ja) ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7023969B2 (ja) ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7049353B2 (ja) 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
CN110088089B (zh) 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
JP6968181B2 (ja) インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP6816107B2 (ja) インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
JP7008704B2 (ja) インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220329

R150 Certificate of patent or registration of utility model

Ref document number: 7050792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250